it's early going but the efficacy data looks to be at least as good as telaprevir - with better pk and at much lower doses no wonder others are jumping on the NS5A bandwagon
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.